Thread: Phase III: Pimavanserin In Patients With Parkinson's Disease Psychosis
View Single Post
Old 04-14-2013, 03:36 PM
johnt johnt is offline
Senior Member
  
Join Date: Apr 2009
Location: Stafford, UK
Posts: 1,059
15 yr Member
johnt johnt is offline
Senior Member
 
Join Date: Apr 2009
Location: Stafford, UK
Posts: 1,059
15 yr Member
Default
"Thu Apr 11, 2013 9:43am EDT

(Reuters) - Acadia Pharmaceuticals Inc said data from an initial late-stage trial would be sufficient to file for approval for its experimental antipsychotic drug for Parkinson's disease patients, ...

Parkinson's disease psychosis is a debilitating disorder that develops in up to 60 percent of patients as their Parkinson's disease progresses.

Most current antipsychotic drugs cannot be used in Parkinson's disease patients as they block dopamine in the brain, which is the primary target for Parkinson's therapy, and can lead to a worsening of motor functions in such patients.

Pimavanserin works by selectively blocking certain serotonin receptors in the brain, but has no effect on dopamine..."

http://www.reuters.com/article/2013/...93A0IA20130411

John
__________________
Born 1955. Diagnosed PD 2005.
Meds 2010-Nov 2016: Stalevo(75 mg) x 4, ropinirole xl 16 mg, rasagiline 1 mg
Current meds: Stalevo(75 mg) x 5, ropinirole xl 8 mg, rasagiline 1 mg
johnt is offline   Reply With QuoteReply With Quote